Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Andrew M.

United Kingdom

Health Economist and Decision Analysis modeller | Modelling Expert in Simul8 and Excel

Profile Summary

I'm an Academic research assistant working at the University of Sheffield in Health Economics and Decision Modelling with vast experience in modelling different healthcare interventions, particularly metabolic diseases, CoViD testing and treatment, and vision problems

Subject Matter Expertise

• ★ Health Economics
• ☆ Decision Science
• ☆ Health Technology Assessment

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Technical Writing

Research Meta-Research, Fact Checking, Systematic Literature Review

Consulting Scientific and Technical Consulting

Data & AI Statistical Analysis

Work Experience

The University of Sheffield

January 2019 - Present

Education

MSc in Health Economics and Decision Modelling

The University of Sheffield

September 2017 - September 2018

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, et al.(2021). Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study . PharmacoEconomics. Springer Science and Business Media {LLC}

Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, et al.(2021). Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study . PharmacoEconomics. Springer Science and Business Media {LLC}

Andrew Metry, Ana Duarte, Simon Walker, Ruth Wong, Jasmina Panovska-Griffiths, Mark Sculpher(2021). Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies . PharmacoEconomics. Springer Science and Business Media {LLC}

Andrew Metry, Ana Duarte, Simon Walker, Ruth Wong, Jasmina Panovska-Griffiths, Mark Sculpher(2021). Jointly modelling economics and epidemiology to support public policy decisions for the COVID-19 response : a review of UK studies . Pharmacoeconomics Italian Research Articles. 39. (8). p. 879--887. Springer Nature

Andrew Metry, Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, et al.(2021). Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT . Health Technology Assessment. 25. (83). NIHR Journals Library

Andrew Metry, Matt Stevenson, Michael Messenger (2021). Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis . Health Technology Assessment.

Andrew Metry, Matt, Michael Messenger(2021). Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis . Health Technology Assessment. 25. (39). National Institute for Health Research

Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, Caroline Murphy, et al.(2021). Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study . Pharmacoeconomics Italian Research Articles. Springer

Andrew Metry, Matt Stevenson, Michael Messenger(2021). Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis . Health Technology Assessment. 25. (21). p. 1--68. National Institute for Health Research

Andrew Metry, Matt, Michael Messenger(2021). Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E : rapid cost-effectiveness analysis . Health Technology Assessment. 25. (21). p. 1--68. National Institute for Health Research

Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, Caroline Murphy, et al. Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study . Pharmacoeconomics Italian Research Articles. Springer Science and Business Media LLC

CONFERENCE PAPER

Andrew Metry, W Sullivan, Benjamin Kearns, Ash Bullement(2019). PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS? . Value in Health. 22. p. S577--S578. Elsevier BV

Andrew Metry, G H Elsisi, Z A Elshafei(2017). COST-MINIMIZATION ANALYSES OF BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS FROM THE EGYPTIAN HEALTHCARE SYSTEM PERSPECTIVE. Value in Health. 20. (9). p. A535--A536.

Andrew Metry, E A Elshikh, I Anan, A A Ebaid, Al Gamal DA, M M Hamed, E A Mouein(2015). A Cross-Sectional Epidemiological Cancer Registry In Egypt . Value in Health. 18. (7). p. A437--A437. Elsevier BV

Andrew Metry, H Elmansy, R Eldessouki, G Elsisi(2015). Cost-Effectiveness of Zoledronic Acid Versus Alendronic Acid In The Treatment of Osteoporosis In Postmenopausal Egyptian Patients: Decision Analysis . Value in Health. 18. (7). p. A646--A646. Elsevier BV

Andrew Metry, Abo A M Taleb, A S Saad, K A Kamal(2015). DEVELOPING HOSPITAL BASED HTA FOR EGYPTIAN CANCER PATIENTS. Value in Health. 18. (3). p. A102--A102.